Ainos Inc. has announced a significant regulatory approval, as its lead drug candidate, VELDONA®, a low-dose oral interferon, has received clearance to begin clinical trials in Taiwan. The trials will focus on treating HIV-related oral warts and primary Sjögren's syndrome (PSS). This milestone marks an important step forward for Ainos in its transition from research and development to commercial execution. The company is also preparing for the launch of scaled pilot programs in the latter half of 2025, leveraging its AI Nose technology across various industries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1039814) on June 16, 2025, and is solely responsible for the information contained therein.